Document is current

Any future updates will be listed below

CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells

Crossref DOI link: https://doi.org/10.1186/2051-1426-2-S3-P80

Published Online: 2014-11-06

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark